ArticlePharmacoEconomics2018

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Amir Ansaripour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.